AI imaging leadership Brainomix is a global pioneer in AI-powered medical imaging focused on stroke and lung diseases, presenting a strong value proposition to health systems seeking automated, high-precision imaging to improve treatment decisions and patient outcomes.

Integrated platform roll-out The Brainomix 360 Stroke is a fully automated imaging platform deployed across hospitals and patient pathways, offering opportunities to partner with health networks and enhance acute stroke workflows regardless of local resources or expertise.

Lung disease acceleration e-Lung technology automatically identifies and quantifies CT features over time, enabling earlier detection of deteriorations in interstitial lung disease and pulmonary fibrosis, which aligns with demand from pulmonology and radiology departments for quantitative ILD tools.

Strategic partnerships Recent collaborations with Endeavor BioMedicines and presence at ERS events indicate a pathway to co-develop and co-market AI imaging analytics for IPF and ILD endpoints, suggesting multi-stakeholder sales approaches with biopharma and research centers.

Expansion and funding readiness Funding and US expansion activity, including a £4.8m funding extension and new US offices, signals capacity to scale deployments in North America and support large hospital networks with scalable AI imaging adoption.